chotic medications, a rare and potentially fatal
condition known as Neuroleptic Malignant Syndrome (NMS) has been reported with
olanzapine. If signs and symptoms appear, immediate discontinuation is
recommended. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity,
altered mental status and evidence of autonomic instability (irregular pulse
or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia).
Additional signs may include elevated creatinine phosphokinase, myoglobinuria
(rhabdomyolysis), and acute renal failure.
Also, as with all antipsychotic treatment, prescribing should be
consistent with the need to minimize Tardive Dyskinesia (TD). The risk of
developing TD and the likelihood that it will become irreversible are believed
to increase as the duration of treatment and the total cumulative dose of
antipsychotic increase. The syndrome may remit, partially or completely, if
antipsychotic treatment is withdrawn.
Other potentially serious adverse events include seizures, elevated
prolactin levels, elevated liver enzymes, cognitive and motor impairment, body
temperature elevation, and trouble swallowing.
The most common treatment-emergent adverse event associated with oral
Zyprexa in placebo-controlled, short-term schizophrenia and bipolar mania
trials was somnolence. Other common events were dizziness, weight gain,
personality disorder (COSTART term for nonaggressive objectionable behavior),
constipation, akathisia, postural hypotension, dry mouth, asthenia, dyspepsia,
increased appetite and tremor.
Full prescribing information, including a boxed warning, is available at
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest researchPage: 1 2 3 4 5 6 Related medicine technology :1
. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy2
. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy3
. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)4
. Bayer Issues Additional Guidance to Physicians on Trasylol(R)5
. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation6
. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues7
. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.8
. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues9
. European Unions CHMP Issues Positive Opinion on Sugammadex10
. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye11
. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders